Clinical Trials
8 trialsNCT04928261 2026-01-22
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
Ottawa Hospital Research Institute
Phase 4 Active not recruiting
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT04962425 2021-07-15
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Peking University Third Hospital
Unknown
NCT04961307 2021-07-14
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Peking University Third Hospital
Unknown
NCT00875238 2018-02-19
PACE in BC
Vanderbilt University Medical Center
Completed
NCT00377780 2015-09-23
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Terminated
NCT00968682 2014-12-31
CADY Study ICORG 08-01
Cancer Trials Ireland
Completed
NCT00016276 2013-01-16
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Terminated